Anthropic Raises $65 Billion and Nears $1 Trillion Value

Anthropic Raises $65 Billion and Nears $1 Trillion Value

Anthropic just raised $65 billion and is nearing a $1 trillion valuation before it goes public. Most people are reading this as a tech story. It’s actually a wealth transfer story, and the window to understand it clearly is closing fast.

SandboxAQ Puts Drug Discovery AI Inside Claude

SandboxAQ Puts Drug Discovery AI Inside Claude

SandboxAQ just brought its molecular simulation models into Claude’s AI platform. Biotech founders can now run drug discovery experiments through plain language queries without building expensive computational infrastructure. The incumbents won’t like what comes next.

SandboxAQ Puts Drug Discovery AI Inside Claude

SandboxAQ Puts Drug Discovery AI Inside Claude

SandboxAQ just plugged its molecular simulation models into Claude, making drug discovery tools accessible without a team of specialists. The average drug costs $2.6 billion to develop. That access barrier just dropped for smaller players.

SandboxAQ Puts Drug Discovery AI Inside Claude

SandboxAQ Puts Drug Discovery AI Inside Claude

SandboxAQ just made its drug discovery models accessible inside Claude, no specialized computing background required. The average drug costs $2.6 billion to develop. That math is about to change for anyone paying attention. Here’s who wins and who gets left behind.

SandboxAQ Drug Discovery Models Now Live in Claude

SandboxAQ Drug Discovery Models Now Live in Claude

SandboxAQ has brought its Large Quantitative Models for molecular simulation into the Claude interface. Drug discovery that once required supercomputers and specialized teams now runs through a browser tab. Here’s what that actually means for pharma, biotech, and anyone paying attention.

SandboxAQ Drug Discovery Comes to Claude Without a PhD

SandboxAQ Drug Discovery Comes to Claude Without a PhD

SandboxAQ connected its drug discovery AI to Claude, putting simulation tools that once cost tens of thousands of dollars into any researcher’s browser. The science story is interesting. The money story is bigger. Here’s who wins and who loses.